A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
Completed
Conditions studied: Nonalcoholic Steatohepatitis (NASH)
In brief
This optional sub study is a part of the phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)
Key facts
- Study ID
- NCT05320146
- Run by
- Corcept Therapeutics
- People needed
- 22
- Starts
- 2022-03-04
- Expected to finish
- 2023-07-18
- Last updated by the study team
- 2024-08-19
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have participated in either Study CORT118335-861 (current study) or Study CORT118335-860 (Corcept Phase 2a NASH study) and received at least one dose of miricorilant; this includes patients who terminated early from the study or completed the study.
- Have not participated in any other clinical trial following study completion in either Study CORT118335-861 or Study CORT118335-860.
Where it is running
- Site 207 — Chandler, Arizona, United States
- Site 209 — Tucson, Arizona, United States
- Site 214 — Panorama City, California, United States
- Site 233 — Santa Ana, California, United States
- Site 211 — Austin, Texas, United States
- Site 213 — Edinburg, Texas, United States
- 305 — Houston, Texas, United States
- Site 212 — San Antonio, Texas, United States
- 226 — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.